Q-omics provides the consensus-scored TNFRSF10C profile across patient tissues and cancer cell-line models. TNFRSF10C expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, TNFRSF10C is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, TNFRSF10C RNA expression shows 20,443 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight DLBC, KIRP, and LSCC as cancer lineages where TNFRSF10C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNFRSF10C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNFRSF10C survival associations across molecular data types. TNFRSF10C RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNFRSF10C RNA expression–survival associations across cancer types. High TNFRSF10C expression shows unfavorable associations in LGG, MESO, LUSC and UVM, but favorable associations in DLBC and HNSC. The DLBC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for TNFRSF10C RNA expression.
This table summarizes TNFRSF10C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRP for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TNFRSF10C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNFRSF10C shows lower tumor expression in LUSC and higher tumor expression in KIRP, COAD, THCA, LIHC and CHOL. The KIRP box plot shows higher TNFRSF10C RNA expression in tumor versus normal tissue (log2 FC = +1.545, t-test p < 0.001).
This table shows molecular features associated with TNFRSF10C in patient tissues and cancer cell lines. In patient samples, TNFRSF10C shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TNFRSF10C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
